Copy of 5 24

 

 

VIVA Rare Tumour Board Webinar

Pediatric Spindle Cell Rhabdomyosarcoma

Wednesday, 15 Dec 2021  |  21.30 - 22:30 (UTC+8 | SGT)  |  Check your Time Zone

 Register Now homeimprovment.info

 

VIVA RARE TUMOUR BOARD WEBINAR is a virtual bi-monthly meeting that is organized by VIVA Foundation for Children with Cancer to enable doctors from all over the world to discuss the diagnosis and treatment of rare pediatric tumours.

 

Join us for a discussion on spindle cell rhabdomyosarcoma. The Hong Kong team will share on the challenges in management for two patients, while Dr Raj Venkatramani, COG Soft Tissue Sarcoma Chair, will enlighten us on the implications and treatment approach after diagnosing such rhabdomyosarcoma variant.

 

 
If you can't make it, you can still register to receive a copy of the webinar recording.

Medical professionals in Singapore may eligible for CME/CPE/CNE credits for attending this webinar.
 
Credits and Certificates of Attendance will only be issued for those who are able to attend the live session and are in adherence with VIVA's Attendance Policy.

 

 

SPEAKER 


Michelle Hermiston

Dr Rajkumar Venkatramani

Director Of Clinical Business Operations at Texas Children's Hospital Cancer and Hematology Centers
Director, Solid Tumor Programs
Director, Soft Tissue Sarcoma Program
Director, Rare Tumors Program
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

Dr Rajkumar Venkatramani is a pediatric oncologist at Texas Children’s Cancer and Hematology Centers and an Associate Professor at Baylor College of Medicine. My area of expertise is pediatric solid tumors, specifically rare cancers, and soft tissue sarcomas. Serving as the chair of the Children’s Oncology Group (COG) Soft tissue sarcoma committee, I play an integral role in the design and conduct of large multi-institutional clinical trials, and in setting research priorities for pediatric
soft tissue sarcomas in North America. I serve as the vice chair for the COG low-risk rhabdomyosarcoma clinical trial (ARST2032) and COG high risk and relapsed Wilms tumor trial (AREN1921). At Texas Children’s Hospital, I am the director of solid and rare tumor programs and the principal investigator for the national rare tumor registry. In my role as the director of
clinical business operations at Texas Children’s Cancer and Hematology Centers, I am involved in faculty education on documentation and billing, identifying new opportunities for increasing revenue and strategic planning.

 

CONVENOR


Michelle Hermiston


Dr Anthony Liu

MBBS, MMedSc, FHKAM (Paed)
Clinical Assistant Professor
Department of Paediatrics & Adolescent Medicine
Hong Kong Children’s Hospital
LKS Faculty of Medicine, The University of Hong Kong


TC Quah

Professor Godfrey Chan

Clinical Professor
Tsao Yen-Chow Endowed Professor in Paediatrics and Adolescent Medicine
Department of Paediatrics and Adolescent Medicine
LKS Faculty of Medicine, The University of Hong Kong


Chief of Service
Department of Paediatrics and Adolescent Medicine,
Hong Kong Children's Hospital / HKU-Shenzhen Hospital / Gleneagles Hospital

 

Prof. Chan graduated from Dentistry (DMD, Cum Laude & Valedictorian 1981) and Medicine (MD, 1985) respectively from University of the East, Philippines and is currently both a registered dentist and medical doctor in Hong Kong. He joined the Department of Pediatrics of the University of Hong Kong in 1989. Then he pursued further training at the St. Jude Children’s Research Hospital, USA as a fellow from 1993 to 1996. He then obtained Dip of Palliative Medicine (1997) from University of Wales and MSc from University of Birmingham (1999). He joined the Faculty of Medicine, University of Hong Kong as Clinical Associate Professor in 1999, and was appointed as the Assistant Dean (External Affair) of the LKS Faculty of Medicine from 2004 to 2013. He was promoted to Clinical Professor in 2009. Since 2012, he has been the Head & Chief of Service of the Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital & HKU-Shenzhen Hospital, The University of Hong Kong. He was awarded Tsao Yen-Chow Endowed Professorship of Pediatrics & Adolescent Medicine in 2013. He is currently the Director of the Molecular Laboratory for Traditional Chinese Medicine, HKU. He has recently been appointed as the Chief of Service and Service Head of Pediatric Oncology for The Hong Kong Children’s Hospital since Oct 2018. He supervised >50 MSc & PhD students and published >300 full articles, 10 book chapters and 1 book. He serves as editor for 12 journals and is the immediate past Chief Editor of Hong Kong Journal of Paediatrics. He received multiple prestigious research grants with a total amount over US$ 6millions. He owned 5 patents including 3 on collagen microsphere device for the delivery of human mesenchymal stem cells. He has multiple International Awards (ANR, SIOP, ASPR, Endeavor Executive Award-Australian Government, Outstanding Pediatrician of APPA) for his clinical and laboratory research works on childhood neurogenic tumors and stem cells biology. His research interest includes the immunological aspects of stem cells, cancers and thalassemia. He is the Immediate Past Chairman of St Jude-VIVA-Asia Pediatric BMT Consortium, Regional Chairman (Asia, Australia & Africa) of Advance in Neuroblastoma Research, Secretary of the Asian Pediatric Hematology Oncology Group, and was the President of Hong Kong Pediatric Society.